Chimeric Therapeutics Limited
CHMMF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.04 | -0.01 | 0.45 |
| FCF Yield | -354.20% | -24.06% | -202.14% | -40.40% |
| EV / EBITDA | 0.41 | -2.84 | -0.24 | -1.14 |
| Quality | ||||
| ROIC | -219.52% | -236.20% | -327.60% | -58.97% |
| Gross Margin | 78.66% | 0.00% | 100.00% | 63.71% |
| Cash Conversion Ratio | 0.70 | 0.60 | 0.63 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.14% | -100.00% | – | – |
| Free Cash Flow Growth | 3.48% | 54.12% | -20.00% | 3.24% |
| Safety | ||||
| Net Debt / EBITDA | 0.63 | -0.05 | 0.10 | 1.35 |
| Interest Coverage | -71.61 | -62.44 | -32.41 | -23.58 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,411.91 | -297,918.17 | 539.36 | -1,801.97 |